Seminars in Oncology
Volume 33 , Pages 44-52 , April 2006

The Role of Alemtuzumab in the Management of T-Cell Malignancies

  • Claire Dearden

      Affiliations

    • Dr Dearden has served as a consultant and speaker for Berlex Oncology and Schering AG.
    • Corresponding Author InformationAddress reprint requests to Claire Dearden, MD, Department of Haemato-oncology, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00061-3

doi: 10.1053/j.seminoncol.2006.01.029

Seminars in Oncology
Volume 33 , Pages 44-52 , April 2006

Article Tools

* Image Usage & Resolution